Alx Oncology Holdings Stock Fundamentals
| ALXO Stock | USD 0.83 0.13 13.54% |
Alx Oncology Holdings fundamentals help investors to digest information that contributes to Alx Oncology's financial success or failures. It also enables traders to predict the movement of Alx Stock. The fundamental analysis module provides a way to measure Alx Oncology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Alx Oncology stock.
At this time, Alx Oncology's Net Interest Income is very stable compared to the past year. As of the 15th of March 2025, Cost Of Revenue is likely to grow to about 1.4 M, while Tax Provision is likely to drop 0.00. Alx | Select Account or Indicator |
Alx Oncology Holdings Company Shares Owned By Insiders Analysis
Alx Oncology's Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Alx Oncology Shares Owned By Insiders | 2.03 % |
Most of Alx Oncology's fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Alx Oncology Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
| Competition |
Based on the latest financial disclosure, 2.03% of Alx Oncology Holdings are shares owned by insiders. This is 86.63% lower than that of the Biotechnology sector and 85.68% lower than that of the Health Care industry. The shares owned by insiders for all United States stocks is 79.88% higher than that of the company.
Alx Oncology Holdings Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Alx Oncology's current stock value. Our valuation model uses many indicators to compare Alx Oncology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Alx Oncology competition to find correlations between indicators driving Alx Oncology's intrinsic value. More Info.Alx Oncology Holdings is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Alx Oncology's Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Alx Oncology's earnings, one of the primary drivers of an investment's value.Alx Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Alx Oncology's direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Alx Oncology could also be used in its relative valuation, which is a method of valuing Alx Oncology by comparing valuation metrics of similar companies.Alx Oncology is currently under evaluation in shares owned by insiders category among its peers.
Alx Fundamentals
| Return On Equity | -0.89 | ||||
| Return On Asset | -0.46 | ||||
| Current Valuation | (73.47 M) | ||||
| Shares Outstanding | 53.38 M | ||||
| Shares Owned By Insiders | 2.03 % | ||||
| Shares Owned By Institutions | 89.35 % | ||||
| Number Of Shares Shorted | 6.45 M | ||||
| Price To Book | 0.39 X | ||||
| Price To Sales | 5,906 X | ||||
| Gross Profit | 107 K | ||||
| EBITDA | (132.25 M) | ||||
| Net Income | (134.85 M) | ||||
| Cash And Equivalents | 313.37 M | ||||
| Cash Per Share | 7.69 X | ||||
| Total Debt | 435 K | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 13.23 X | ||||
| Book Value Per Share | 2.14 X | ||||
| Cash Flow From Operations | (121.91 M) | ||||
| Short Ratio | 8.93 X | ||||
| Earnings Per Share | (2.58) X | ||||
| Target Price | 2.93 | ||||
| Number Of Employees | 80 | ||||
| Beta | 1.01 | ||||
| Market Capitalization | 44.38 M | ||||
| Total Asset | 147.78 M | ||||
| Retained Earnings | (621.12 M) | ||||
| Working Capital | 115.85 M | ||||
| Net Asset | 147.78 M |
About Alx Oncology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Alx Oncology Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Alx Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Alx Oncology Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 9.5 M | 8.4 M | |
| Cost Of Revenue | 752.4 K | 1.4 M | |
| Stock Based Compensation To Revenue | 4.14 | 4.35 | |
| Sales General And Administrative To Revenue | 11.28 | 11.84 | |
| Research And Ddevelopement To Revenue | 22.05 | 23.15 | |
| Capex To Revenue | 0.03 | 0.03 | |
| Revenue Per Share | 0.03 | 0.03 | |
| Ebit Per Revenue | (42.48) | (40.36) |
Pair Trading with Alx Oncology
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alx Oncology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alx Oncology will appreciate offsetting losses from the drop in the long position's value.Moving together with Alx Stock
Moving against Alx Stock
| 0.77 | IVA | Inventiva Sa | PairCorr |
| 0.77 | LLY | Eli Lilly | PairCorr |
| 0.75 | VIGL | Vigil Neuroscience | PairCorr |
| 0.71 | PBH | Prestige Brand Holdings | PairCorr |
| 0.64 | MGTX | MeiraGTx Holdings PLC Downward Rally | PairCorr |
The ability to find closely correlated positions to Alx Oncology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Alx Oncology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Alx Oncology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Alx Oncology Holdings to buy it.
The correlation of Alx Oncology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alx Oncology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alx Oncology Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Alx Oncology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Alx Oncology Piotroski F Score and Alx Oncology Altman Z Score analysis. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alx Oncology. If investors know Alx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alx Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Alx Oncology Holdings is measured differently than its book value, which is the value of Alx that is recorded on the company's balance sheet. Investors also form their own opinion of Alx Oncology's value that differs from its market value or its book value, called intrinsic value, which is Alx Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alx Oncology's market value can be influenced by many factors that don't directly affect Alx Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alx Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alx Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alx Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.